Analysis Oryzon Genomics S.A. (0RDB)
5/29/2024
Analysis of Oryzon Genomics S.A. (0RDB)
Oryzon Genomics S.A. is a biopharmaceutical company focused on developing epigenetic therapies for oncology and neurodegenerative diseases. The company's stock, with the symbol 0RDB, has shown some interesting trends in the recent data:1. **Price Movement**: The stock price has been fluctuating between 1.874 and 2.020 in the past month, showing some volatility but also some stability in the range.
2. **Technical Indicators**:
- **RSI Indicator**: The Relative Strength Index (RSI) values have been around 45-60, indicating a moderate level of momentum in the stock.
- **MACD Indicator**: The Moving Average Convergence Divergence (MACD) values have been positive, suggesting a bullish trend.
- **Moving Averages**: The Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA) have been relatively close to each other, indicating a stable trend.
3. **Overall Analysis**: Based on the technical indicators, the stock seems to be in a moderate bullish phase with some volatility. Investors may want to monitor the RSI and MACD values for potential trend changes.
Please note that this analysis is based on historical data and does not guarantee future performance. It's always recommended to conduct thorough research and consider other factors before making investment decisions.
Earnings estimate
The analysts' estimates for future quarterly and annual earnings per share are as follows:1. Current Quarter (as of June 30, 2024):
- Average Estimate: $1.33
- Low Estimate: $1.27
- High Estimate: $1.36
- Year Ago EPS: $1.26
- Number of Analysts: 26
2. Next Quarter (as of September 30, 2024):
- Average Estimate: $1.53
- Low Estimate: $1.44
- High Estimate: $1.63
- Year Ago EPS: $1.46
- Number of Analysts: 25
3. Current Year (as of September 30, 2024):
- Average Estimate: $6.59
- Low Estimate: $6.43
- High Estimate: $6.92
- Year Ago EPS: $6.13
- Number of Analysts: 39
4. Next Year (as of September 30, 2025):
- Average Estimate: $7.23
- Low Estimate: $6.40
- High Estimate: $7.90
- Year Ago EPS: $6.59
- Number of Analysts: 39
Based on these estimates, we can see a generally positive trend in the expected earnings per share for both the upcoming quarters and the next two years. The average estimates are showing growth compared to the year-ago EPS figures, indicating optimism among analysts regarding the company's performance.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.
Growth estimates
Based on the consensus estimates provided:- The current year growth rate is 7.5%
- The next quarter growth rate is 4.8%
- The current quarter growth rate is 5.6%
- The next year growth rate is 9.7%
- The next 5 years compound annual growth rate (CAGR) is 11%
- The past 5 years compound annual growth rate (CAGR) is 20.15%
It can be observed that the company is expected to experience a significant increase in growth compared to the past 5 years, with a particularly strong growth rate projected for the next 5 years. This indicates positive sentiment and potential opportunities for the company in the near future.
Price target
Based on the analysts' forecast, the future price of the security is expected to range between $164 (low) and $250 (high), with a median estimate of $200 and an average estimate of $202.26. The current price of the security is $191.57.Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits for a particular company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio and a high total debt to equity ratio. The profit margin and operating margin are also healthy, indicating good financial performance. The company's fiscal year ends in September 2023, and the most recent quarter reported is March 2024. The company shows a solid return on assets and return on equity.
Looking at stock statistics, the company has a low short ratio and a significant percentage of shares held by institutions. The stock price has a beta of 1.264 and has shown a change between the fifty-two-week low and high.
Valuation metrics show a relatively high PEG ratio and forward PE ratio. The company's market capitalization and enterprise value are substantial, with high price to book and price to sales ratios. The enterprise value to EBITDA and enterprise value to revenue ratios are also notable.
The stock price summary includes moving averages, fifty-two-week low and high prices, and the beta value.
Lastly, dividends and splits data show dividend rates, yield, payout ratio, dividend dates, and information about past stock splits.
Income statement 💸
These are the revenues. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. The gross profit margin has been fluctuating, with a peak in 2022 at $170.8 billion and a slight decrease in 2023 to $169.1 billion.
3. Operating income has shown an upward trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
4. Net income has also been increasing consistently, with a significant rise from $57.4 billion in 2020 to $97 billion in 2023.
5. Earnings per share (EPS) have shown a slight variation over the years, with diluted EPS ranging from 3.28 in 2020 to 6.13 in 2023.
6. The company has been able to maintain a stable number of outstanding shares over the years, indicating no significant dilution of shares.
7. Overall, the financial performance of the company in terms of revenue generation has been positive, showing growth in sales, income, and profitability.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has been fluctuating, with the highest value in 2018 at $107,147,000,000.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has been relatively stable over the years, indicating consistent operational performance.
3. The company has been paying a significant amount in income taxes each year, with the highest amount paid in 2021.
4. The end cash position has also varied, reaching its peak in 2020 and its lowest point in 2022.
5. Financing activities have had a major impact on the cash flow, with significant amounts being used for common stock repurchase and debt issuance and payments.
6. Investing activities show a mix of acquisitions, investments, and capital expenditures, with varying levels of cash flow impact each year.
These conclusions provide insights into the company's financial performance and management of cash flow over the years.
MACD of 0RDB
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
